Pregabalin as adjunctive treatment for focal onset seizures in pediatric patients: A randomized controlled trial
Journal of Child Neurology Mar 22, 2019
Antinew J, et al. - In this investigation, researchers tested pregabalin as for safety and effectiveness as adjunctive treatment in children (aged 4-16 years) with partial-onset seizures, now called focal onset seizures. Criteria for inclusion was experiencing focal seizures and having a stable 1 to 3 antiepileptic drug regimen. Pregabalin 2.5 mg/kg/d, 10 mg/kg/d or placebo were used in the study, with doses increased to 3.5 or 14 mg/kg/d for subjects weighing <30 kg. Common adverse events included somnolence, increased weight and increased appetite. According to this double-blind, randomized, placebo-controlled, international study, pregabalin 10 mg/kg/d showed effectiveness in reducing seizure frequency in children with focal seizures vs placebo; both doses of pregabalin were generally safe and well tolerated.
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries